Tackling ALK in Non-Small Cell Lung Cancer: The Role of Novel Inhibitors

Translational Lung Cancer Research - Hong Kong
doi 10.21037/tlcr.2016.06.10
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

AME Publishing Company

Related search

Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2012English

P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer

Cancer Research
Cancer ResearchOncology
2008English

P2.13-07 CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice
Oncology
2019English

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2018English

The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2010English

Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer

Journal of Cancer
Oncology
2015English

EMT Is Associated With, but Does Not Drive Resistance to ALK Inhibitors Among EML4-ALK Non-Small Cell Lung Cancer

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy